CN108314695B - 一种异种双核金属配合物的制备及应用 - Google Patents
一种异种双核金属配合物的制备及应用 Download PDFInfo
- Publication number
- CN108314695B CN108314695B CN201810008461.1A CN201810008461A CN108314695B CN 108314695 B CN108314695 B CN 108314695B CN 201810008461 A CN201810008461 A CN 201810008461A CN 108314695 B CN108314695 B CN 108314695B
- Authority
- CN
- China
- Prior art keywords
- complex
- metal complex
- preparation
- heterogeneous
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000004696 coordination complex Chemical class 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title abstract description 14
- 238000002428 photodynamic therapy Methods 0.000 abstract description 13
- 238000002595 magnetic resonance imaging Methods 0.000 abstract description 12
- 229910052741 iridium Inorganic materials 0.000 abstract description 9
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 abstract description 7
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract description 6
- XJJWWOUJWDTXJC-UHFFFAOYSA-N [Mn].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 Chemical compound [Mn].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 XJJWWOUJWDTXJC-UHFFFAOYSA-N 0.000 abstract description 5
- 238000006862 quantum yield reaction Methods 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 229910052751 metal Inorganic materials 0.000 description 9
- 239000002184 metal Substances 0.000 description 9
- 238000000862 absorption spectrum Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000003504 photosensitizing agent Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 5
- 239000002872 contrast media Substances 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000005298 paramagnetic effect Effects 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- ZKSVYBRJSMBDMV-UHFFFAOYSA-N 1,3-diphenyl-2-benzofuran Chemical compound C1=CC=CC=C1C1=C2C=CC=CC2=C(C=2C=CC=CC=2)O1 ZKSVYBRJSMBDMV-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000005291 magnetic effect Effects 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- SGRHVVLXEBNBDV-UHFFFAOYSA-N 1,6-dibromohexane Chemical compound BrCCCCCCBr SGRHVVLXEBNBDV-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- QJXCFMJTJYCLFG-UHFFFAOYSA-N 2,3,4,5,6-pentafluorobenzaldehyde Chemical compound FC1=C(F)C(F)=C(C=O)C(F)=C1F QJXCFMJTJYCLFG-UHFFFAOYSA-N 0.000 description 2
- BRARRAHGNDUELT-UHFFFAOYSA-N 3-hydroxypicolinic acid Chemical compound OC(=O)C1=NC=CC=C1O BRARRAHGNDUELT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- 239000002616 MRI contrast agent Substances 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229910001437 manganese ion Inorganic materials 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 230000005408 paramagnetism Effects 0.000 description 2
- 150000004032 porphyrins Chemical class 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 150000000921 Gadolinium Chemical class 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229940082328 manganese acetate tetrahydrate Drugs 0.000 description 1
- CESXSDZNZGSWSP-UHFFFAOYSA-L manganese(2+);diacetate;tetrahydrate Chemical compound O.O.O.O.[Mn+2].CC([O-])=O.CC([O-])=O CESXSDZNZGSWSP-UHFFFAOYSA-L 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0033—Iridium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Radiology & Medical Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种异种双核金属配合物的制备及应用。该异核配合物由铱配合物和锰卟啉配合物组成,结构通式如下;本发明的配合物具有较高的弛豫效率,可以实现磁共振成像应用;同时该配合物具有较高的单线态氧量子产率,可以在细胞内产生ROS并通过观察细胞前后形态的变化,证明其具有较好的光动力治疗效果。该发明所述的配合物在磁共振成像与光动力治疗方面有着广阔的应用前景。
Description
技术领域
本发明属于有机光电材料技术领域,具体涉及一类具有成像-治疗双功能的异种双核金属配合物的制备方法及其在磁共振成像、光动力治疗领域中的应用研究。
背景技术
磁共振成像(MRI)利用强磁场中被共振频率的射频波所激发的原子核释放出的电磁波重建物体内部的结构图像,这种技术具有无辐射损伤、高的横向和纵向分辨率等特点,已成功地应用于许多疾病的临床诊断。为了增强信号对比度和提高软组织图像的分辨率,越来越多的人们开始研究造影剂。
顺磁性造影剂一般由顺磁性金属离子和配体组成,又为T1类型造影剂。顺磁性金属离子主要有Gd3+,Mn2+,和Fe3+等元素周期表中稳定价态的镧系和第四周期过渡元素。顺磁性钆配合物是临床上应用最广泛的MRI造影剂。然而,最近的研究报道Gd3+以离子形式注入生物活体时,易在肝、脾和骨中累积,具有很高的毒性。锰离子,由于其高效的T1增强效果而成为很好的造影剂候选材料。由于其增加的核自旋弛豫率,锰卟啉配合物已成为一种很有潜力的MRI造影剂。
光动力治疗(PDT)是一种通过特定波长的光激发光敏剂,使之产生过量的活性氧物种(ROS)杀死病灶处细胞的治疗方法。光动力治疗法对生物组织无损伤,并且已经获得了临床批准,现在已被广泛应用于癌症治疗之中。同时,光敏剂受到了研究人员越来越多的关注。理想的光敏剂应当具有高的单线态到三线态系间串越效率、极低的细胞暗毒性,以及高的消光系数。由于金属铱配合物具有优异的光物理学性质(如:大的斯托克位移、吸收光谱及荧光光谱受配体调节、较高的发光量子产率和较长的磷光寿命等),其作为在生物体荧光成像的荧光探针和光动力学治疗光敏剂方面受到越来越广泛的关注。
本发明这两方面出发,将具有磁共振成像功能的锰卟啉和具有优异单线态氧生成的铱配合物以共价键的形式连接在一起,实现同时具有磁共振成像和光动力治疗功能的异种双核金属配合物。
发明内容
发明目的:提供一种具有成像-治疗双功能的异种双核金属配合物的制备方法及其应用研究。
本发明的具有光动力治疗效果的异种双核金属配合物的制备是将铱配合物和锰卟啉配合物通过共价键连接起来,使其不仅可以具有顺磁性,还能具有高的单线态氧量子产率,从而在磁共振成像、和光动力治疗领域具有良好的应用前景。
本发明是一类具有成像-治疗双功能的异种双核金属配合物,具有如下结构通式:
其中,R为:
其中,n为1~12的自然数
其中,Ar为:
具有成像-治疗双功能的异种双核金属配合物的合成路线如下:
具体是以五氟苯甲醛和对甲氧基苯甲醛为原料,用Lindsey法合成卟啉,得到的卟啉再进行脱甲氧基反应,然后与金属锰盐进行配位,得到的锰卟啉配合物与1,6-二溴己烷发生取代反应。3-羟基-2-吡啶甲酸与金属铱二氯桥进行配位,得到的铱配合物与带有卤代烷基链的锰卟啉配合物进行取代反应,最终得到异种双核金属配合物。
所述的异种双核金属配合物,其特征在于该材料应用于磁共振成像。
所述的异种双核金属配合物,其特征在于该材料应用于光动力治疗领域。
有益效果:本发明的异种双核金属配合物具有顺磁性,有着较高的弛豫效率,是性能优良的造影剂。
本发明的异种双核金属配合物具有较高的单线态氧产率、高的生物安全性,是高效的光敏剂。
本发明的异种双核金属配合物可应用于磁共振成像,光动力治疗,具有简单的化学结构和良好的生物相容性,是性能优异的MRI成像造影剂和光动治疗光敏剂。
附图说明
图1.实施例3中异种双核金属配合物的质谱表征;
图2.实施例4中异种双核金属配合物的甲醇溶液(50μM)紫外-可见吸收光谱;
图3.实施例5中异种双核金属配合物浓度为15μM、DPBF浓度为20μM的甲醇溶液在475nm光照下的吸收光谱;
图4.实施例6中弛豫率1/T1对不同Mn3+摩尔浓度的线性关系图。
具体实施方式
下面对本发明的实施例作详细说明,本实施例在以本发明技术方案为前提下进行实施,给出了详细的实施方式和具体的操作过程,但本发明的保护范围不限于下述的实例。
实施例1:铱配合物的制备
化合物2的制备:3-羟基2-吡啶甲酸(0.14mmol)和铱二氯桥(0.06mmol)在乙二醇乙醚(8mL)溶剂中,在氮气气氛下110℃搅拌回流24h,后将反应溶液降温至室温,反应结束后减压蒸馏除去有机溶剂,并将得到的固体过柱子提纯,得到红色粉末状固体。产率36%。
实施例2:锰卟啉配合物的制备
化合物2的制备:将五氟苯甲醛(0.9mmol)、对甲氧基苯甲醛(2.7mmol)加入到反应瓶中,抽真空,加入二氯甲烷(250mL)、吡咯(3.6mmol),鼓氮气20min,加入三氟化硼乙醚(0.4mmol),常温搅拌3h,再加入DDQ(1.8mmol),继续反应1h,抽滤,减压将滤液中的DCM旋去,柱色谱纯化,得到2。产率12%。1HNMR(400MHz,CDCl3)δ9.02(d,J=4.5Hz,2H),8.91(d,J=13.1Hz,4H),8.82(d,J=4.4Hz,2H),8.13(d,J=8.4Hz,2H),7.33(d,J=8.5Hz,2H),1.55(s,3H),-2.82(s,2H)。
化合物3的制备:将2(0.1mmol)加入到反应瓶中,抽真空,加入二氯甲烷(10mL)、三溴化硼(2.5mmol),25℃下搅拌12h,二氯甲烷萃取,干法上样,柱色谱纯化,得到3。产率69%。1H NMR(400MHz,CDCl3)δ9.01(d,J=4.7Hz,2H),8.89(d,J=3.2Hz,4H),8.82(d,J=4.6Hz,2H),8.08(d,J=8.3Hz,2H),7.27(s,1H),7.25(s,1H),-2.83(s,2H)。
化合物4的制备:将3(0.1mmol)、四水合醋酸锰(1mmol)加入到反应瓶中,抽真空,加入甲醇(6mL)、三乙胺(2mL),60℃下搅拌3h,降至室温,二氯甲烷萃取,干法上样,柱色谱纯化,得到4。产率89%。
化合物5的制备:将4(0.1mmol)、碳酸钾(1.0mmol)加入到反应瓶中,抽真空,加入乙腈(9mL)、1,6-二溴己烷(0.6mmol),85℃下搅拌12h,降至室温,二氯甲烷萃取,干法上样,柱色谱纯化,得到5。产率76%。
实施例3:异种双核金属配合物的制备
化合物6的制备:将1(2.5μmol)、5(2.5μmol)、碳酸钾(25μmol)加入到反应瓶中,抽真空,加入N,N-二甲基甲酰胺(12mL),85℃下搅拌12h,降至室温,二氯甲烷萃取,干法上样,柱色谱纯化,得到6。
实施例4:异种双核金属配合物的质谱测试
本发明采用的质谱测试浓度为50μM,溶剂为二氯甲烷。质谱数据如图1所示,结合中间体的核磁及质谱验证最终产物的结构。
实施例5:异种双核金属配合物的吸收光谱测试
本发明采用的光谱测试浓度为50μM,测试溶剂为甲醇。配合的吸收光谱如图2所示。配合物在可见光区650nm表现出了较强的吸收,特别是该配合物能够被可见光激发,在做细胞成像实验时大大减少了激发光源对细胞的损伤。
实施例6:异种双核金属配合物的单线态氧的测定
本发明采用的测定了异种双核金属配合物含量为15μM、DPBF浓度为20μM的甲醇溶液在4.8mW/cm2 475nm光照下DPBF吸收光谱的变化。变化如图3所示。随着光照时间的增长,DPBF吸收光谱逐渐降低。说明所发明的异种金属可以产生单线态氧,为此可以用于光动力治疗。
实施例7:异种双核金属配合物的MRI测试
准备5个含材料的一系列浓度梯度的1.2mL离心管,在25℃下用中尺寸磁共振成像仪测试材料的T1弛豫时间。使用核磁共振分析应用软件,用IR序列采集样品信号,利用反演软件反演出相应弛豫信息。图4展示了弛豫率1/T1(R1)对不同Mn3+摩尔浓度的线性关系图,随着锰离子浓度的增大,弛豫率不断增强。
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810008461.1A CN108314695B (zh) | 2018-01-04 | 2018-01-04 | 一种异种双核金属配合物的制备及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810008461.1A CN108314695B (zh) | 2018-01-04 | 2018-01-04 | 一种异种双核金属配合物的制备及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108314695A CN108314695A (zh) | 2018-07-24 |
CN108314695B true CN108314695B (zh) | 2020-06-16 |
Family
ID=62893000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810008461.1A Active CN108314695B (zh) | 2018-01-04 | 2018-01-04 | 一种异种双核金属配合物的制备及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108314695B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111250692B (zh) * | 2018-11-30 | 2021-11-09 | 中国科学院大连化学物理研究所 | 一种溶液中稳定的异核双金属原子材料 |
CN110845544B (zh) * | 2019-11-26 | 2022-04-05 | 南京邮电大学 | 一种可捕获单线态氧的离子型磷光铱(iii)配合物及其制备方法和应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5262532A (en) * | 1991-07-22 | 1993-11-16 | E.R. Squibb & Sons, Inc. | Paramagnetic metalloporphyrins as contrast agents for magnetic resonance imaging |
CN1215341A (zh) * | 1996-04-01 | 1999-04-28 | Epix医学公司 | 生物活化的诊断成像造影剂 |
CN101090710A (zh) * | 2004-10-25 | 2007-12-19 | 宝利策尼克斯有限公司 | 治疗和/或诊断用途的含聚磷腈的可负载颗粒和制备方法及其应用 |
CN101805362A (zh) * | 2010-03-30 | 2010-08-18 | 中国医学科学院生物医学工程研究所 | 二乙撑三胺五乙酸钆修饰的卟啉及制备方法及用途 |
CN105440044A (zh) * | 2015-12-22 | 2016-03-30 | 南京邮电大学 | 不同结构框架金属卟啉金属配合物的制备方法和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7368570B2 (en) * | 2003-08-07 | 2008-05-06 | University Of Southern California | Organometallic complexes as singlet oxygen sensitizers |
-
2018
- 2018-01-04 CN CN201810008461.1A patent/CN108314695B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5262532A (en) * | 1991-07-22 | 1993-11-16 | E.R. Squibb & Sons, Inc. | Paramagnetic metalloporphyrins as contrast agents for magnetic resonance imaging |
CN1215341A (zh) * | 1996-04-01 | 1999-04-28 | Epix医学公司 | 生物活化的诊断成像造影剂 |
CN101090710A (zh) * | 2004-10-25 | 2007-12-19 | 宝利策尼克斯有限公司 | 治疗和/或诊断用途的含聚磷腈的可负载颗粒和制备方法及其应用 |
CN101805362A (zh) * | 2010-03-30 | 2010-08-18 | 中国医学科学院生物医学工程研究所 | 二乙撑三胺五乙酸钆修饰的卟啉及制备方法及用途 |
CN105440044A (zh) * | 2015-12-22 | 2016-03-30 | 南京邮电大学 | 不同结构框架金属卟啉金属配合物的制备方法和应用 |
Non-Patent Citations (2)
Title |
---|
Manganese porphyrin-incorporated conjugated polymer nanoparticles for T1-enhanced magnetic resonance and fluorescent imaging;Tianshe Yang等;《Inorganica Chimica Acta》;20170708;604-611 * |
Phosphorescent Iridium(III) Complexes for Bioimaging;Zhang Kenneth Yin等;《Structure and Bonding》;20141030;131-180 * |
Also Published As
Publication number | Publication date |
---|---|
CN108314695A (zh) | 2018-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021102951A4 (en) | Multimodal phototheranostic agent with aggregation-induced emission properties, and preparation and application thereof | |
CN101805362B (zh) | 二乙撑三胺五乙酸钆修饰的卟啉及制备方法及用途 | |
CN108102408B (zh) | 一种基于氮杂氟硼烷的近红外染料的制备及应用 | |
CN111171595B (zh) | 一类氮杂氟硼二吡咯近红外荧光染料及制备方法 | |
CN108314695B (zh) | 一种异种双核金属配合物的制备及应用 | |
CN112159522B (zh) | 一种水溶性罗丹明基荧光/比色双模式探针及其制备方法与应用 | |
CN107573366B (zh) | 邻羧基苯甲醛缩1,3-丙二胺席夫碱铜配合物的制备方法 | |
CN108795088A (zh) | 一种具有增强光动力和光热效果的近红外染料及其制备和应用 | |
Li et al. | Aggregation-induced phosphorescent emission-active Ir (iii) complexes with a long lifetime for specific mitochondrial imaging and tracking | |
CN110642882B (zh) | 一种兼具双氧水检测和光动力杀伤癌细胞活性的荧光探针及其制备方法和应用 | |
CN112851556B (zh) | 新型聚集诱导发光高尔基体荧光探针及其制备方法与应用 | |
Han et al. | A diphenylacrylonitrile conjugated porphyrin with near-infrared emission by AIE–FRET | |
CN111039853B (zh) | 一种可用于光声成像和光热治疗的铁配合物及其制备方法和用途 | |
CN113072574A (zh) | 一种氟硼甲瓉类近红外二区荧光染料、制备方法及应用 | |
Coban | Magnetic and photophysical properties of new TbIII–based two-dimensional hydrogen-bonded polymer | |
CN108101901B (zh) | 活性氧依赖性的硫化氢荧光探针及其制备方法与应用 | |
CN107522773B (zh) | 一种五肽改性罗丹明b化合物及其制备方法和应用 | |
CN112047876B (zh) | 红色双光子荧光aie化合物及其合成和应用 | |
CN113336799A (zh) | 一种含双氰基铱配合物及其制备方法和应用 | |
CN101822846B (zh) | 一种磁光双模式分子影像探针及其制备方法 | |
Semenishyn et al. | LANTHANIDE-PORPHYRINS AND LANTHANIDE-PHTHALOCYANINES: DEVELOPMENT OF STABLE AND EFFECTIVE INFRARED 4F-EMITTIVE COMPOUNDS | |
CN108101916B (zh) | 一种水溶性卟啉配合物的制备及应用 | |
Li et al. | Heterobimetallic lanthanide tetrahedral cages: Synthesis, design and application for potential multimodal imaging contrast agent | |
Aita et al. | NIR fluorescent ytterbium compound for in vivo fluorescence molecular imaging | |
CN114573524B (zh) | 一种有机配体、金属有机框架材料及其应用和制备方法、中间体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |